Skip to main content
. 2023 May 3;10(20):2206213. doi: 10.1002/advs.202206213

Figure 4.

Figure 4

Antitumor growth efficacy of NCPA in subcutaneous graft Lewis lung carcinoma‐bearing mice. A) A schematic illustration showing in vivo administration scheme for Lewis lung carcinoma‐bearing mice after different indication treatments of IgG, aCD47 (100 µg), aPD‐L1 (100 µg), and CP or NCPA at low (50 µg aCD47+50 µg aPD‐L1), medium (100 µg aCD47+100 µg aPD‐L1), and high (200 µg aCD47+200 µg aPD‐L1) dosages (n = 5). B) The tumor average volumes. C) The survival plots. D) The trajectory of tumor growth from indicated treatments. PD, progressive disease; PR, partial response; CR, complete response. E) H&E staining images of tumor tissues from mice after different indicated treatments.